Should I buy or sell AVROBIO stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AVRO shares. View AVRO analyst ratings or view top-rated stocks .

What is AVROBIO's stock price target for 2024?

3 Wall Street analysts have issued 1-year price objectives for AVROBIO's shares. Their AVRO share price targets range from $2.00 to $6.00. On average, they predict the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 203.0% from the stock's current price. View analysts price targets for AVRO or view top-rated stocks among Wall Street analysts .

How have AVRO shares performed in 2023?

AVROBIO's stock was trading at $0.7129 at the start of the year. Since then, AVRO stock has increased by 85.2% and is now trading at $1.32. View the best growth stocks for 2023 here .

Are investors shorting AVROBIO?

AVROBIO saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 964,900 shares, a drop of 58.2% from the October 31st total of 2,310,000 shares. Based on an average trading volume of 343,700 shares, the short-interest ratio is presently 2.8 days. Currently, 2.5% of the company's shares are sold short. View AVROBIO's Short Interest .

When is AVROBIO's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our AVRO earnings forecast .

How were AVROBIO's earnings last quarter?

AVROBIO, Inc. (NASDAQ:AVRO) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.21.

What other stocks do shareholders of AVROBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVROBIO investors own include Sorrento Therapeutics (SRNE) , ImmunoGen (imgn) , Aduro Biotech (ADRO) , Aldeyra Therapeutics (ALDX) , Amarin (AMRN) , Biohaven (BHVN) , Nabriva Therapeutics (NBRV) , Selecta Biosciences (SELB) , VBI Vaccines (vbiv) and Arbutus Biopharma (ABUS) .

When did AVROBIO IPO?

(AVRO) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.

Who are AVROBIO's major shareholders?

AVROBIO's stock is owned by many different institutional and retail investors. Top institutional investors include BML Capital Management LLC (8.99%), Newtyn Management LLC (4.49%), Acadian Asset Management LLC (3.87%), Terrapin Asset Management LLC (1.25%), Affinity Asset Advisors LLC (1.12%) and Aldebaran Capital LLC (1.06%). View institutional ownership trends .

How do I buy shares of AVROBIO?

Shares of AVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

AVROBIO Stock Price, News & Analysis (NASDAQ:AVRO)

$1.32

+0.10 (+8.20%)

(As of 11/30/2023 ET)

Compare

Today's Range: $1.21
▼
$1.32
50-Day Range: $1.22
▼
$1.62
52-Week Range: $0.57
▼
$1.93

Volume: 321,108 shs
Average Volume: 1.33 million shs
Market Capitalization: $58.83 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

AVROBIO MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 203.0% Upside
$4.00 Price Target
Short Interest: Healthy
2.52% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.96
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From $0.58 to ($0.48) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

399th out of 949 stocks

Biological Products, Except Diagnostic Industry

69th out of 163 stocks

3.3

Analyst's Opinion

Consensus Rating
AVROBIO has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, AVROBIO has a forecasted upside of 203.0% from its current price of $1.32.
Amount of Analyst Coverage
AVROBIO has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.52% of the float of AVROBIO has been sold short.
Short Interest Ratio / Days to Cover
AVROBIO has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in AVROBIO has recently decreased by 58.23%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
AVROBIO does not currently pay a dividend.
Dividend Growth
AVROBIO does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AVRO.

2.8

News and Social Media Coverage

News Sentiment
AVROBIO has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for AVROBIO this week, compared to 1 article on an average week.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AVROBIO insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.20% of the stock of AVROBIO is held by insiders.
Percentage Held by Institutions
59.95% of the stock of AVROBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for AVROBIO are expected to decrease in the coming year, from $0.58 to ($0.48) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AVROBIO is -13.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AVROBIO is -13.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AVROBIO has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AVROBIO Stock (NASDAQ:AVRO)

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

AVRO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AVRO Stock News Headlines

November 29, 2023 | americanbankingnews.com

AVROBIO (NASDAQ:AVRO) Stock Price Down 0.8%

November 14, 2023 | morningstar.com

Avrobio Inc AVRO

December 1, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 14, 2023 | markets.businessinsider.com

Potential Growth and Strategic Alternatives: Reasons Behind Zhu’s Buy Rating for Avrobio

November 8, 2023 | finance.yahoo.com

Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?

October 6, 2023 | finance.yahoo.com

Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?

October 5, 2023 | msn.com

AvroBio (AVRO) Price Target Increased by 12.82% to 3.74

September 25, 2023 | ca.finance.yahoo.com

AVROBIO, Inc. (AVRO)

December 1, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

September 11, 2023 | benzinga.com

Solu Therapeutics Appoints Philip Vickers, Ph.D., as President and Chief Executive Officer

August 12, 2023 | msn.com

Avrobio: Net-Net Biotech Pursuing Strategic Alternatives

August 11, 2023 | markets.businessinsider.com

Avrobio (AVRO) Gets a Buy from Barclays

August 7, 2023 | finance.yahoo.com

Arbor Biotechnologies Appoints Deanna M. Petersen as Chief Business Officer

July 13, 2023 | nasdaq.com

Wells Fargo Maintains AvroBio (AVRO) Overweight Recommendation

July 13, 2023 | finance.yahoo.com

AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%

July 13, 2023 | bizjournals.com

Five things you need to know today, and the Sumner Tunnel closure’s real test

July 12, 2023 | benzinga.com

Wedbush Downgrades Avrobio to Neutral, Announces $2 Price Target

July 12, 2023 | seekingalpha.com

Avrobio to explore strategic options; halts studies

July 12, 2023 | msn.com

Why Avrobio Shares Are Rising Wednesday

July 12, 2023 | marketwatch.com

Avrobio Shares Rise 38% After Move to Explore Strategic Alternatives

July 12, 2023 | msn.com

Wedbush Downgrades AvroBio (AVRO)

July 12, 2023 | bizjournals.com

Gene therapy startup Avrobio explores a sale

July 12, 2023 | markets.businessinsider.com

AVROBIO To Conduct Exploration Of Strategic Alternatives - Quick Facts

July 12, 2023 | finance.yahoo.com

AVROBIO to Explore Strategic Alternatives

June 28, 2023 | finance.yahoo.com

AVRO - AVROBIO, Inc.

June 27, 2023 | fool.com

Avrobio (NASDAQ: AVRO)

June 12, 2023 | seekingalpha.com

Avrobio completes sale of gene therapy program to Novartis for $87.5M

See More Headlines

Receive AVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AVRO
CUSIP: N/A
CIK: 1681087
Web: www.avrobio.com
Phone: (617) 914-8420
Fax: N/A
Employees: 78
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $6.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +203.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 2.28
P/E Growth: N/A
Net Income: $-105,890,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -97.36%
Return on Assets: -79.74%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.44
Quick Ratio: 14.44

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.31 per share
Price / Book: 0.57

Miscellaneous

Outstanding Shares: 44,570,000
Free Float: 40,473,000
Market Cap: $58.83 million
Optionable: Not Optionable
Beta: 1.39

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Erik John Ostrowski M.B.A. (Age 51)
President, Interim Chief Executive Officer, CFO & Treasurer
Comp: $947.29k
Ms. Azadeh Golipour Ph.D. (Age 44)
Chief Technology Officer
Comp: $728.21k
Mr. Jeffrey Medin Ph.D.
Scientific Founder
Mr. Steven N. Avruch J.D. (Age 62)
Chief Legal Officer & Secretary
Comp: $506.68k
Mr. Scott Gottesman
Vice President of Human Resource
Mr. Andreas Kouri
Senior Vice President of Global Supply Chain & External Manufacturing
Dr. Essra Ridha FFPM (Age 42)
M.D., Chief Medical Officer
Ms. Kirsten Dupuis
Chief of Staff

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

AVRO Stock Analysis - Frequently Asked Questions

Should I buy or sell AVROBIO stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AVRO shares.
View AVRO analyst ratings or view top-rated stocks.
What is AVROBIO's stock price target for 2024?: 3 Wall Street analysts have issued 1-year price objectives for AVROBIO's shares. Their AVRO share price targets range from $2.00 to $6.00. On average, they predict the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 203.0% from the stock's current price.
View analysts price targets for AVRO or view top-rated stocks among Wall Street analysts.
How have AVRO shares performed in 2023?: AVROBIO's stock was trading at $0.7129 at the start of the year. Since then, AVRO stock has increased by 85.2% and is now trading at $1.32.
View the best growth stocks for 2023 here.
Are investors shorting AVROBIO?: AVROBIO saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 964,900 shares, a drop of 58.2% from the October 31st total of 2,310,000 shares. Based on an average trading volume of 343,700 shares, the short-interest ratio is presently 2.8 days. Currently, 2.5% of the company's shares are sold short.
View AVROBIO's Short Interest.
When is AVROBIO's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our AVRO earnings forecast.
How were AVROBIO's earnings last quarter?: AVROBIO, Inc. (NASDAQ:AVRO) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.21.

What other stocks do shareholders of AVROBIO own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AVROBIO investors own include Sorrento Therapeutics (SRNE), ImmunoGen (imgn), Aduro Biotech (ADRO), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Biohaven (BHVN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), VBI Vaccines (vbiv) and Arbutus Biopharma (ABUS).
When did AVROBIO IPO?: (AVRO) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.
Who are AVROBIO's major shareholders?: AVROBIO's stock is owned by many different institutional and retail investors. Top institutional investors include BML Capital Management LLC (8.99%), Newtyn Management LLC (4.49%), Acadian Asset Management LLC (3.87%), Terrapin Asset Management LLC (1.25%), Affinity Asset Advisors LLC (1.12%) and Aldebaran Capital LLC (1.06%).
View institutional ownership trends.
How do I buy shares of AVROBIO?: Shares of AVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AVRO) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial